Echo Therapeutics Announces Needle-free Glucose Monitoring System

The company has patented its Symphony tCGM glucose monitoring system, and the Prelude SkinPrep transdermal drug delivery product.

Echo Therapeutics Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the receipt of a notice of allowance for a patent application covering its Prelude SkinPrep System and a notice of issuance for a patent covering its Symphony tCGM System.

Echo Therapeutics received notice that its U.S. Patent Application No. 10/792,862 entitled "Method and Apparatus for Enhancement of Transdermal Transport" has been allowed.  Echo Therapeutics also received notice that its patent application entitled "Transdermal Analyte Monitoring Systems and Methods for Analyte Detection" issued as Russian Patent No. 2444980 and will expire in 2028 if all maintenance fees are timely paid.

"These new patents strengthen our patent portfolio for our non-invasive, glucose monitoring technology," said Patrick T. Mooney, M.D., Echo's Chairman and CEO.  "We believe that our intellectual property portfolio will provide our products with long-term market protection and will add to shareholder value in the near- and long-term."

These patents join seven U.S. patents and nearly 70 foreign patents already obtained by Echo Therapeutics.  Approximately 30 patent applications by Echo are pending in the U.S. and foreign countries.

Source: Echo Therapeutics Inc.

No votes yet